Axcella Health Inc.
Axcella Health Inc. (AXLA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
axla · stock forecast · 10 analysts (3M) · FMP · updated Oct 11, 2024
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$60.00
Consensus
$60.00
+1210.0% upside
Low
$60.00
Median: $60 · Last Close: $4.58
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.58 | ↑ 0.00% |
1-day model range: $4.58–$4.58. Peak: $4.58 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · AXLA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-02-16 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-02-15 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2022-12-16 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2022-12-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-12-15 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2022-12-14 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-11-02 | Chardan Capital | Maintains | Buy→Buy |
| 2022-11-01 | Chardan Capital | Maintains | Buy→Buy |
| 2022-10-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-10-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Axcella Health Inc. (AXLA) stock. Of the recent 41 rating actions, 0 were upgrades and 8 were downgrades. 10 analysts currently cover AXLA.
Analyst Recommendation Trends
AXLA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-5.00
EPS Next Year
$-5.00
↑ 0.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast AXLA EPS of $-5.00 for the current fiscal year, based on estimates from 1 analysts. The AXLA revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AXLA stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AXLA price target is $60.00 (+1210.0% upside), with an analyst consensus of Buy.
The AXLA short-term stock prediction for tomorrow is $4.58 (+0.00%).
Axcella Health Inc. trades on NASDAQ under the ticker AXLA. The AXLA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
AXLA forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month AXLA price target is $60.00, with a high forecast of $60.00 and a low of $60.00. The median price target is shown in the chart above when available. This implies +1210.0% potential upside from the current price of $4.58.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.